Thomas Amatruda

7.9k total citations
66 papers, 3.8k citations indexed

About

Thomas Amatruda is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Thomas Amatruda has authored 66 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 19 papers in Molecular Biology and 19 papers in Genetics. Recurrent topics in Thomas Amatruda's work include CAR-T cell therapy research (29 papers), Virus-based gene therapy research (16 papers) and Cutaneous Melanoma Detection and Management (14 papers). Thomas Amatruda is often cited by papers focused on CAR-T cell therapy research (29 papers), Virus-based gene therapy research (16 papers) and Cutaneous Melanoma Detection and Management (14 papers). Thomas Amatruda collaborates with scholars based in United States, United Kingdom and Canada. Thomas Amatruda's co-authors include Melvin I. Simon, G. Virginia Upton, M I Simon, Howard L. Kaufman, René González, Vladlen Z. Slepak, David A. Steele, Neil Senzer, John Nemunaitis and Henry Fong and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Thomas Amatruda

66 papers receiving 3.6k citations

Peers

Countries citing papers authored by Thomas Amatruda

Since Specialization

Citations

This map shows the geographic impact of Thomas Amatruda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Amatruda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Amatruda more than expected).

Fields of papers citing papers by Thomas Amatruda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Amatruda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Amatruda. The network helps show where Thomas Amatruda may publish in the future.

Co-authorship network of co-authors of Thomas Amatruda

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Amatruda. A scholar is included among the top collaborators of Thomas Amatruda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Amatruda. Thomas Amatruda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study 2022 ·American Journal of Obstetrics and Gynecology ·L. Phuong, Austin Miller, Amanda Black, Roni T. Falk, John F. Boggess, Katherine Tucker, Ashley Stuckey, Gustavo C. Rodriguez, Cheung Wong, Thomas Amatruda, (unknown), Susan C. Modesitt, S. Diane Yamada, Kristin Bixel, Gretchen Glaser, Peter G. Rose, Mark H. Greene, Mark E. Sherman	3
2	Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma 2019 ·EBioMedicine ·Robert H.I. Andtbacka, Thomas Amatruda, John Nemunaitis, Jonathan S. Zager, John Walker, Jason Chesney, (unknown), Cheng‐Pang Hsu, Cheryl A. Pickett, Janice M. Mehnert	47
3	Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses 2018 ·Journal for ImmunoTherapy of Cancer ·Robert O. Dillman, Andrew N. Cornforth, Gabriel I. Nistor, Edward F. McClay, Thomas Amatruda, Carol DePriest	58
4	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial 2016 ·Annals of Surgical Oncology ·Robert H.I. Andtbacka, Merrick Ross, Igor Puzanov, Mohammed Milhem, Frances A. Collichio, Keith A. Delman, Thomas Amatruda, Jonathan S. Zager, Lee D. Cranmer, Eddy C. Hsueh, Lisa Chen, Mark Shilkrut, Howard L. Kaufman	240
5	Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment 2015 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Edward F. McClay, Neil M. Barth, Thomas Amatruda, Lee S. Schwartzberg, (unknown), Cristina de Leon, (unknown), Carol DePriest	18
6	Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. 2014 ·Journal of Clinical Oncology ·Howard L. Kaufman, Robert Hans Ingemar Andtbacka, Frances A. Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith A. Delman, Lynn E. S̄pitler, Igor Puzanov, Yining Ye, Li Ai, Jennifer Gansert, Robert S. Coffin, Merrick I. Ross	36
7	Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy 2012 ·Journal of Immunotherapy ·Robert O. Dillman, Andrew N. Cornforth, Carol DePriest, Edward F. McClay, Thomas Amatruda, Cristina de Leon, (unknown), (unknown), Denysha Carbonell, (unknown)	60
8	A randomized phase 2 study of temozolomide and bevacizumab or nab ‐paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma 2012 ·Cancer ·Lisa A. Kottschade, Vera J. Suman, Domingo G. Pérez, Robert R. McWilliams, Judith S. Kaur, Thomas Amatruda, Francois J. Geoffroy, Howard M. Gross, Peter A. Cohen, Anthony J. Jaslowski, Matthew Kosel, Svetomir N. Markovic	64
9	Is age ≥70years an important predictor of adverse events among patients enrolled in metastatic melanoma trials? Findings from pooled analyses of therapeutic trials 2012 ·Journal of Geriatric Oncology ·Aminah Jatoi, Jacob B. Allred, Vera J. Suman, Edward T. Creagan, Gary A. Croghan, Thomas Amatruda, Svetomir N. Markovic	2
10	A phase II trial of nab‐paclitaxel (ABI‐007) and carboplatin in patients with unresectable stage IV melanoma 2010 ·Cancer ·Lisa A. Kottschade, Vera J. Suman, Thomas Amatruda, Robert R. McWilliams, Bassam Mattar, Daniel A. Nikcevich, Robert J. Behrens, Tom R. Fitch, Anthony J. Jaslowski, Svetomir N. Markovic	79
11	Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma 2010 ·Clinical Cancer Research ·Kazuo Koyanagi, Steven O’Day, Peter D. Boasberg, Michael B. Atkins, Hong Wang, René González, Karl D. Lewis, John A. Thompson, Clay M. Anderson, Jose Lutzky, Thomas Amatruda, (unknown), Jon Richards, Jeffrey S. Weber, Dave S.�B. Hoon	52
12	Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma 2008 ·Cancer ·Domingo G. Pérez, Vera J. Suman, Tom R. Fitch, Thomas Amatruda, Roscoe F. Morton, (unknown), Costas L. Constantinou, James R. Egner, Lisa A. Kottschade, Svetomir N. Markovic	99
13	High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial 2005 ·Journal of Clinical Oncology ·Jon Richards, A. Y. Bedikian, René González, Michael B. Atkins, Eric D. Whitman, Jose Lutzky, Mark A. Morse, Thomas Amatruda, E. Galanis, Joyce Thompson	5
14	A phase II multi-center trial of maintenance biotherapy (MBT) after induction concurrent biochemotherapy (BCT) for patients (Pts) with metastatic melanoma (MM) 2005 ·Journal of Clinical Oncology ·Steven O’Day, Michael B. Atkins, Jeffrey S. Weber, John A. Thompson, Colin R. Anderson, René González, Jose Lutzky, Thomas Amatruda, E. Hersh, Peter D. Boasberg	7
15	A phase 2 trial of high-dose Allovectin-7 in patients with advanced metastatic melanoma 2004 ·Journal of Clinical Oncology ·Jon Richards, A. Y. Bedikian, René González, Michael B. Atkins, Eric D. Whitman, Jose Lutzky, Mark A. Morse, Thomas Amatruda, E. Galanis	1
16	Specific interactions of chemoattractant factor receptors with G-proteins 1993 ·Journal of Biological Chemistry ·Thomas Amatruda, Norma P. Gerard, Craig Gérard, M I Simon	173
17	Evolution of the mammalian G protein α subunit multigene family 1992 ·Nature Genetics ·Thomas M. Wilkie, Debra J. Gilbert, A. Olsen, Xiao–Ning Chen, Thomas Amatruda, (unknown), B. J. Trask, Peter J. de Jong, Randall R. Reed, M I Simon, Nancy A. Jenkins, Neal G. Copeland	210
18	The 35- and 36-kDa beta subunits of GTP-binding regulatory proteins are products of separate genes. 1988 ·Journal of Biological Chemistry ·Thomas Amatruda, (unknown), Henry Fong, John K. Northup, M I Simon	61
19	Battered women: a concern for the medical profession. 1986 ·PubMed ·(unknown), Elena L. Pollard, (unknown), (unknown), (unknown), Thomas Amatruda	5
20	Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. 1984 ·PubMed ·Koeffler Hp, Thomas Amatruda, N. IKEKAWA, Yusuke Kobayashi, DeLuca Hf	193

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact